UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000040584
Receipt No. R000046318
Scientific Title A Clinical Study of the Efficacy and Safety of Corticosteroids for Cancer-induced Neuropathic Pain.
Date of disclosure of the study information 2020/06/01
Last modified on 2020/05/29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A Clinical Study of the Efficacy and Safety of Corticosteroids for Cancer-induced Neuropathic Pain.
Acronym A Clinical Study of the Efficacy and Safety of Corticosteroids for Cancer-induced Neuropathic Pain.
Scientific Title A Clinical Study of the Efficacy and Safety of Corticosteroids for Cancer-induced Neuropathic Pain.
Scientific Title:Acronym A Clinical Study of the Efficacy and Safety of Corticosteroids for Cancer-induced Neuropathic Pain.
Region
Japan

Condition
Condition Cancer pain
Classification by specialty
Medicine in general Anesthesiology Adult
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate the effectiveness and safety of systemic administration of corticosteroids for the treatment of cancer induced central and peripheral neuropathic pain.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes To compare the difference of pain intensity (worst pain in 24 hours) between baseline, 72 hours later and 168 hours later.
Key secondary outcomes

In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required.

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
999 years-old >
Gender Male and Female
Key inclusion criteria Patients over 20 years old
Patients who have been diagnosed with cancer.
Patients in the hospital
Patients with cancer pain (Brief Pain Inventory short form; worst pain intensity score of 4 or higher in the past 24 hours)
Patients will be scheduled to receive regular corticosteroids for the treatment of cancer-induced neuropathic pain
Key exclusion criteria Patients whose physicians consider it inappropriate to participate in the research.
Patients who are pregnant, lactating, or may be pregnant.
Patients with diabetes who have poor glycemic control who need additional insulin injections
Patients with an infection-caused fever of 38 degrees or higher
Patients undergoing treatment for an active gastrointestinal ulcer
Patients with diagnoses of hematological malignancy
Serious adverse events due to corticosteroid in the past
Patients who started a new anticancer treatment with a molecularly targeted agency or immune checkpoint inhibitor within 2 weeks, or are scheduled to start the treatment within 1 week
Patients were administrated corticosteroids more than the scheduled dose on the day before the start of treatment
Patients scheduled to administrate corticosteroids more than its regular doses in one week for the treatment of adverse effects by anticancer therapy
Patients who are scheduled to receive surgery for the pain control in a week
Target sample size 200

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Tagami
Organization Tohoku University Graduate School of Medicine
Division name Palliative Medicine
Zip code
Address 2-1, Seiryo-machi, Aobaku, Sendai, Miyagi, 9808575, Japan
TEL 0227177366
Email keita.tagami.d7@tohoku.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Tagami
Organization Tohoku University Graduate School of Medicine
Division name Palliative Medicine
Zip code
Address 2-1, Seiryo-machi, Aobaku, Sendai, Miyagi, 9808575, Japan
TEL 0227177366
Homepage URL
Email keita.tagami.d7@tohoku.ac.jp

Sponsor
Institute Tohoku University Graduate School of Medicine
Institute
Department

Sponsor means an organization that is responsible for plan, deployment and
report of the research including funding management. It doesn't mean
funding agency". Therefore, all clinical trial should have the one.

Funding Source
Organization Japan Science and Technology Agency
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 06 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2020 Year 02 Month 03 Day
Date of IRB
Anticipated trial start date
2020 Year 06 Month 01 Day
Last follow-up date
2021 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Prospective Observational Study
The patients who admit in the hospital from June 6 2020 to December 31 2021 are registered.

Management information
Registered date
2020 Year 05 Month 29 Day
Last modified on
2020 Year 05 Month 29 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046318


Contact us.